News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Robert H. Getzenberg

Articles by Robert H. Getzenberg

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

ByAdam M. Brufsky, MD, PhD,Hannah M. Linden, MD,Hope S. Rugo, MD,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Erica L. Mayer, MD, MPH

April 18th 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

ByElgene Lim, MBBS, FRACP, PhD,Adam M. Brufsky, MD, PhD,Hope S. Rugo, MD,Charles L. Vogel, MD, FACP,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Hannah M. Linden, MD

April 18th 2022

Latest Updated Articles

Trending on CancerNetwork

FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer

How Might CTO1681 Prevent CRS After CAR T-Cell Therapy in DLBCL?

© 2025 MJH Life Sciences^®

All rights reserved.